- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07645222
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC
A PHASE Ib STUDY OF THE SAFETY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY OF HS-20122 COMBINED THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Guangdong
-
Guangzhou, Guangdong, Kina
- Rekruttering
- Ethics Committee of Sun Yat-sen University Cancer Center
-
Ta kontakt med:
- Ran Xu, MD
- Telefonnummer: 86-20-87343009
- E-post: llwyh@sysucc.org.cn
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Locally advanced or metastastic NSCLC;
- Received at least 1 line SoC,or treatment naïve;
- With at least 1 target lesion according to RECIST 1.1.
- Appropriate organ function
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1 and no deterioration within 2 weeks prior to the first dose.
- Minimum expected survival longer than 12 weeks
- Female subjects of childbearing potential are willing to take appropriate contraceptive measures and should not breastfeed from signing the informed consent form (ICF) through 6 months after the last dose; male subjects are willing to use barrier contraception (i.e., condom) from signing the ICF through 6 months after the last dose.
- Voluntarily participate in this clinical trial, understand the study procedures, and be able to sign written informed consent form.
Exclusion Criteria:
- Insufficient wash out duration of prior systemic anticancer therapy
- Local radiotherapy within 2 weeks prior to first dose of investigational drug
- Pleural/abdominal effusion requires clinical intervention
- Major surgery within 4 weeks prior to first dose of investigational drug
- History of drugs may prolong QT interval
- Have any grade ≥ 2 residual toxicity according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0) from prior anti-tumor therapy (except alopecia and residual neurotoxicity).
- Presence of brain metastasis or carcinomatous meningtitis
- History of other primary malignancies
- Significant, uncontrolled, or active cardiovascular diseases
- Severe or poorly controlled diabetes
- Extremely obesity or emaciation
- Clinically significant bleeding symptoms or obvious bleeding tendency within 1 month prior to the first dose
- Severe arteriovenous thrombotic events (e.g., deep venous thrombosis, pulmonary embolism) within 3 months prior to the first dose
- Severe infection within 4 weeks
- History of systemic glucocorticoids over 28 days prior to first dose of investigational drug
- Presence of known active infectious diseases,
- Prensence of ophthalmological abnormalities.
17.Presence of hepatic encephalopathy, Hepato-renal Syndrome 18.Presence or history of confirmed or suspected ILD; 19.Prior history of significant neurological or mental disorders, including conditions that interfere with assessment, such as epilepsy, dementia, or major depressive disorder.
20.History of severe allergy, or history of hypersensitivity to any active or inactive ingredient of investigational drugs.
21.Presence of any conditions that jeopardize subject safety or interfere with study assessments as judged by the investigator.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: HS-20122+Aumolertinib
|
EGFR mut NSCLC, receive HS-20122+Aumolertinib
|
|
Eksperimentell: HS-20122+Adbrelimab
|
EGFRwt NSCLC,receive HS-20122+Adbrelimab
|
|
Eksperimentell: HS-20122+Adbrelimab+Platinum-based Chemo
|
EGFR wt NSCLC,receive HS-20122+Adbrelimab+ Platinum-based Chemo
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
SAE
Tidsramme: Gjennom hele forsøkets varighet, omtrent 2 år
|
forekomst av undersøker vurderte alvorlige bivirkninger, gradert etter CTCAE V5.0
|
Gjennom hele forsøkets varighet, omtrent 2 år
|
|
RP2D for Combination
Tidsramme: Through the full duration of this trial, approximately 2 years
|
To evaluate the potent and tolerated of combination(s) and dosage(s) of HS-20122 based therapy in subjects with locally advanced or metastatic NSCLC who have experienced disease progression on or after prior treatment, which suitable for a Phase II trial
|
Through the full duration of this trial, approximately 2 years
|
|
ORR
Tidsramme: Through the full duration of this trial, approximately 2 years;
|
Investigator evaluated overall response rate, to evaluate the efficacy of each combination;
|
Through the full duration of this trial, approximately 2 years;
|
|
TEAE
Tidsramme: Through the full duration of this trial, approximately 2 years;
|
incidence of Investigator evaluated Treatment Emerged Adverse Events, graded per CTCAE V5.0
|
Through the full duration of this trial, approximately 2 years;
|
|
TRAE
Tidsramme: Through the full duration of this trial, approximately 2 years;
|
incidence of Investigator evaluated Treatment Related Adverse Events, graded per CTCAE V5.0
|
Through the full duration of this trial, approximately 2 years;
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Duration of Response
Tidsramme: Through the full duration of this trial ,approximately 2 years
|
Investigator evaluated Duration of Response
|
Through the full duration of this trial ,approximately 2 years
|
|
Disease Control Rate
Tidsramme: Through the full duration of this trial ,approximately 2 years;
|
Investigator evaluated Disease Control Rate
|
Through the full duration of this trial ,approximately 2 years;
|
|
Progression Free Survival
Tidsramme: Through the full duration of this trial, approximately 2 years;
|
Investigator evaluated duration of Progression Free Survival
|
Through the full duration of this trial, approximately 2 years;
|
|
Overall Survival
Tidsramme: Through the full duration of this trial ,approximately 2 years;
|
Investigator evaluated duration of Overall Survival
|
Through the full duration of this trial ,approximately 2 years;
|
|
PK parameter
Tidsramme: Through the full duration of this trial, approximately 2 years;
|
blood concentration of combo agents
|
Through the full duration of this trial, approximately 2 years;
|
|
Immuogencity
Tidsramme: Through the full duration of this trial ,approximately 2 years;
|
positive rate of drug specific antibody
|
Through the full duration of this trial ,approximately 2 years;
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- HS-20122-103
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .